HCM
BOLT icon

Hawkeye Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

Hawkeye Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$432K Hold
20,752
– – 1.06% 5
2023
Q2 		$531K Hold
20,752
– – 1% 7
2023
Q1 		$577K Hold
20,752
– – 0.97% 8
2022
Q4 		$540K Hold
20,752
– – 0.5% 16
2022
Q3 		$614K Hold
20,752
– – 0.4% 22
2022
Q2 		$847K Hold
20,752
– – 0.46% 25
2022
Q1 		$1.14M Buy
20,752
+12,352
+147% +$831K 0.45% 28
2021
Q4 		$823K Buy
+8,400
New +$1.59M 0.33% 34

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hawkeye Capital Management's BOLT Position: Q3 2023 in Review

Hawkeye Capital Management held its Bolt Biotherapeutics (BOLT) position steady in Q3 2023 at 20,752 shares worth $432K. The position accounts for 1.06% of the portfolio, ranked #5.

Hawkeye Capital Management first reported a position in BOLT in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.14M in Q1 2022. 34 funds tracked by Wall St. Rank hold BOLT as of Q3 2023.

  • Hawkeye Capital Management held 20,752 shares of Bolt Biotherapeutics worth $432K as of Q3 2023.
  • Hawkeye Capital Management left its Bolt Biotherapeutics share count unchanged in Q3 2023.
  • Bolt Biotherapeutics made up 1.06% of Hawkeye Capital Management's portfolio in Q3 2023, its #5 holding.
  • Hawkeye Capital Management first reported a position in Bolt Biotherapeutics in Q4 2021 and has held it in 8 quarters since.
  • Hawkeye Capital Management's Bolt Biotherapeutics position peaked at $1.14M in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2023.

Based on Hawkeye Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.